Radiopharmaceuticals are reshaping oncology and targeted cancer therapies, offering new hope to patients through highly targeted treatments. With the industry bracing for a surge of late-stage trials, we are facing a shift that will multiply operational demands and pressure already-limited resources.
This reality raises a critical question for central labs, imaging CROs, and their logistics partners: How can we scale capacity, expertise, and collaboration to meet the coming demand?
Download Now
